What is King Pharmaceuticals's market cap?

King Pharmaceuticals (KG) has a market capitalization of $81.9M and trades on XNYS.

What is King Pharmaceuticals's revenue and profitability?

King Pharmaceuticals generated $43.4M in trailing twelve-month revenue with net income of $57.0M, representing a net margin of 131.4%. These figures are based on the Q1 2026 filing.

Who are King Pharmaceuticals's competitors?

King Pharmaceuticals's key competitors include Everest Group, Ltd., Arch Capital Group Ltd., KKR & Co. Inc., and others. These companies compete in similar markets and product categories.

What subsidiaries does King Pharmaceuticals have?

King Pharmaceuticals's subsidiaries include Maiden Holdings, Ltd., Kestrel Group LLC.

Where is King Pharmaceuticals headquartered?

King Pharmaceuticals is headquartered in United States of America. It has been publicly traded since 2025.

King Pharmaceuticals

Kestrel Group Ltd is a specialty program insurance group formed through the combination of Kestrel LLC and Maiden Holdings.

Market cap

$81.92M-67.0%

Revenue$43.4M+1,160%

Net income$57.0M—

EPS (diluted)$13.30—

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 8, 2026

Revenue$10.2MMiss by $336.3M EPS-$1.34

Read the full report

Next report

Aug 7, 2026 (In 3 weeks)

Revenue estimate$338.6M

Financials

Q1 2026

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation & ratios

Valuation

See full

Market cap$81.92M-67.0%

Enterprise value$196.43M-48.8%

P/E1.4×—

P/S1.9×-27.0×

Returns & leverage

See full

Debt / equity1.5×—

Competitors

By market cap

KKR & Co.$86.4B-28.4%

Arch Capital Group$35.5B+6.0%

Everest Group$14.7B+3.3%

SiriusPoint$2.9B+26.2%

Skyward Specialty Insurance Group, Inc.$2.4B+9.8%

Tiptree Inc.$687.5M-22.6%

King Pharmaceuticals$81.9M-66.1%

EZR

Reliance Global Group, Inc.$2.3M—

By revenue growth

King Pharmaceuticals+1,160%

KKR & Co.+34.8%

Skyward Specialty Insurance Group, Inc.+28.8%

SiriusPoint+22.9%

Arch Capital Group+8.8%

Everest Group-0.6%

Tiptree Inc.-45.3%

By net margin

King Pharmaceuticals131.45%—

Arch Capital Group24.63%+3.9pp

SiriusPoint15.38%+8.4pp

KKR & Co.14.33%-0.1pp

Everest Group11.76%-0.7pp

Skyward Specialty Insurance Group, Inc.11.36%+1.1pp

Tiptree Inc.-0.679%+1.5pp

Profile

Kestrel Group Ltd is a specialty program insurance group formed through the combination of Kestrel LLC and Maiden Holdings. The company operates a capital-light, fee-based insurance platform focused on generating recurring income through program services while managing the run-off of legacy reinsurance and alternative asset portfolios. Its core value proposition centers on optimizing shareholder returns by leveraging underwriting capacity and utilizing significant tax assets.

Competitive position

Kestrel Group is a specialized player in the program services niche, transitioning from a traditional reinsurance model to a fee-oriented insurance platform.

GeographiesGlobal

Customer segmentsFinancial Institutions, Insurance Companies

Business modelFee-for-service, Asset-light, Underwriting

SuppliersCapital Markets, Insurance Carrier Partners, Regulatory Authorities

CustomersSpecialty Insurance Programs, Policyholders, Reinsurance Buyers

CountryUnited States of America

Listed2025

CEOBradford Luke Ledbetter

FilingsSEC EDGAR

Ask your AI about King Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's market cap?: King Pharmaceuticals (KG) has a market capitalization of $81.9M and trades on XNYS.
What is King Pharmaceuticals's revenue and profitability?: King Pharmaceuticals generated $43.4M in trailing twelve-month revenue with net income of $57.0M, representing a net margin of 131.4%. These figures are based on the Q1 2026 filing.
Who are King Pharmaceuticals's competitors?: King Pharmaceuticals's key competitors include Everest Group, Ltd., Arch Capital Group Ltd., KKR & Co. Inc., and others. These companies compete in similar markets and product categories.
What subsidiaries does King Pharmaceuticals have?: King Pharmaceuticals's subsidiaries include Maiden Holdings, Ltd., Kestrel Group LLC.
Where is King Pharmaceuticals headquartered?: King Pharmaceuticals is headquartered in United States of America. It has been publicly traded since 2025.